Covaxin Data Silent On Protocol Breach

INDIA-MADE Covaxin shows 77.8 per cent effectiveness in symptomatic infections of sars-cov-2, as per the phase-3 clinical trial data released by the vaccine's manufacturer, Bharat Biotech. The preprint paper, uploaded to the online archive and distribution server medRxiv on July 2, says Covaxin has an efficacy of 93.4 per cent against severe covid-19 infections and 65.2 per cent against the Delta variant.

- 

The vaccine's phase-3 trials took place between November 16, 2020, and January 7, 2021. The release of the trial data has brought back focus on the breach of protocol at People's Hospital Bhopal, one of the vaccine's trial sites, as reported by the media in January. The reports claimed the hospital lured participants by not specifying that they were part of a t